



# List of guidance from ECDC and recent publications on COVID-19

COVID-19 Digest  
05 May 2022

## ECDC Outputs

### Recent publications

**Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose** Technical report – 28 Apr [Read more »](#)

**Transitioning beyond the acute phase of the COVID-19 pandemic: Approaches and tools used by a sample of EU countries in the transition and de-escalation phase – interim report** Technical report – 27 Apr [Read more »](#)

**Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA** Technical report – 21 Apr [Read more »](#)

**Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines** 06 Apr [Read more »](#)

**Information to guide individual health assessment of refugees fleeing the war in Ukraine – Considerations for healthcare workers** UNHCR, ECDC, IOM, WHO/Europe 06 Apr [Read more »](#)

**Guidance for the prevention and control of COVID-19 in temporary reception centres in the context of the large numbers of people fleeing Ukraine** Technical report – 18 Mar [Read more »](#)

**Analysis of COVID-19 contact tracing data from Ireland, Italy and Spain – 2020 data** Technical report – 15 Mar [Read more »](#)

**Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV/2 among individuals aged 30 years and older, ECDC multi-country study – second update** Technical report – 14 Mar [Read more »](#)

**Operational public health considerations for the prevention and control of infectious diseases in the context of Russia's aggression towards Ukraine** 08 Mar [Read more »](#)

### Situation updates on COVID-19

**COVID-19 situation update for the EU/EEA:** Includes an update on the number of cases and deaths and geographical distribution of 14-day notification rates for the EU/EEA. [Read more »](#)

**COVID-19 situation update worldwide:** Includes an update on the number of cases and deaths and geographical distribution of 14-day notification rates worldwide. [Read more »](#)

**COVID-19 country overview:** Provides an overview of the evolving epidemiological situation for the EU/EEA (including case/death notification rates, testing rates, test positivity, hospital and ICU occupancy/capacity per country, vaccination uptake at EU/EEA and country level). [Read more »](#)

**Situation dashboard:** Interactive map with the latest available data on COVID-19 (worldwide). [Read more »](#)

**Vaccine tracker:** Real time data on national vaccine doses distribution and vaccine update within EU/EEA countries.

[Read more »](#)

**Maps in support of the Council Recommendation** on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the EU/EEA. These maps are published every Thursday based on a number of different indicators. [Read more »](#)

**Response Measures Database** of ECDC and the Joint Research Centre (JRC) of the European Commission is a regularly updated archive of non-pharmaceutical interventions introduced by 30 countries in the EU/EEA. [Read more »](#)

## Updates on SARS-CoV-2 variants

**SARS-CoV-2 variants of concern:** Overview of the different variants that are currently being considered of concern and of interest as assessed by ECDC. [Read more »](#)

**Variants of concern.** The ECDC country overview includes an own section on variants of concern. It includes e.g. a map of sequencing volume, variant data table and weekly variant distribution by country. [Read more »](#)

**Dashboard on SARS-CoV-2 variants.** This dashboard provides an overview of the proportion of variants of concern and variants of interest in EU/EEA Member States together with sequencing volumes and complements the ECDC country overview report. [Read more »](#)

## Download data on COVID-19

Much of ECDC's data can be downloaded from its website. This for instance includes, but is not limited to, reported number of cases and deaths, 14-day case notification rates, ICU and hospital admissions/occupancy, testing rates/positivity, vaccination data and response measures implemented in EU/EEA countries. [Link to downloadable data»](#)

## Other ECDC Outputs

**ECDC website on COVID-19** – [Read more »](#)

**ECDC surveillance definitions for COVID-19.** [Read more »](#)

**Find the latest evidence on:**

- [Coronaviruses](#)
- [Risk factors and risk groups](#)
- [Transmission of COVID-19](#)
- [COVID-19 infection](#)
- [Clinical characteristics of COVID-19](#)
- [Diagnostic testing and screening for SARS-CoV-2](#)
- [Immune responses and immunity to SARS-CoV-2](#)
- [Treatment and pharmaceutical prophylaxis](#)
- [COVID-19 vaccines](#)

**Prevention and control of COVID-19** – how to protect yourself, risk groups, COVID-19 vaccination, patient and case management. [Read more »](#)

**Q & A on COVID-19 aimed at public and lay audience** – Questions and answers. [Read more »](#)

## Infographics, Videos, Webinars and more

**Infographics and leaflets about COVID-19** – Infographics, leaflets and posters on COVID-19. [Read more »](#)

**Videos on COVID-19** – What do we know about the COVID-19. [Read more »](#)

**ECDC Virtual Academy (EVA)** – COVID-19 Micro learning for public health professionals. [Read more »](#)

## Recent peer-reviewed publications

**Disclaimer:** In view of the large number of COVID-19 related publications, this list is compiled based on a rapid review of titles and abstracts and subjective selection of peer-reviewed articles and does not include an additional qualitative assessment or critical appraisal of the evidence by ECDC.

1. COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity *Sci Adv* [Read more »](#)
2. Data-driven prediction of COVID-19 cases in Germany for decision making *BMC Med Res Methodol* [Read more »](#)
3. Genomic and epidemiological report of the recombinant XJ lineage SARS-CoV-2 variant, detected in northern Finland, January 2022 *Euro Surveill* [Read more »](#)
4. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022 *Euro Surveill* [Read more »](#)
5. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study *Lancet Infect Dis* [Read more »](#)
6. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design *Lancet Infect Dis* [Read more »](#)
7. Challenges to evidence-informed decision-making in the context of pandemics: qualitative study of COVID-19 policy advisor perspectives *BMJ Glob Health* [Read more »](#)
8. COVID-19 pandemic in shelters for asylum seekers: a scoping review of preventive measures *BMJ open* [Read more »](#)
9. Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves *Pediatr Res* [Read more »](#)
10. Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel *Nat Commun* [Read more »](#)
11. Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland *Eur J Clin Microbiol Infect Dis* [Read more »](#)
12. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years *Lancet Reg Health Eur* [Read more »](#)
13. Association of SARS-CoV-2 Infection During Pregnancy With Maternal and Perinatal Outcomes *JAMA* [Read more »](#)
14. Factors Associated with Non-Severe Adverse Reactions after Vaccination against SARS-CoV-2: A Cohort Study of 908,869 Outpatient Vaccinations in Germany *Vaccines* [Read more »](#)
15. Trends and associated factors for Covid-19 hospitalisation and fatality risk in 2.3 million adults in England *Nat Commun* [Read more »](#)
16. Seroprevalence of SARS-CoV-2 in German secondary schools from October 2020 to July 2021: a longitudinal study *Infection* [Read more »](#)
17. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study *Lancet Respir Med* [Read more »](#)
18. Transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) between hospital workers and members of their household: Nationwide, registry-based, cohort study from Norway *Infect Control Hosp Epidemiol* [Read more »](#)
19. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents *JAMA Cardiol* [Read more »](#)
20. Impact of population mixing between vaccinated and unvaccinated subpopulations on infectious disease dynamics: implications for SARS-CoV-2 transmission *CMAJ* [Read more »](#)
21. Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis *JAMA Netw Open* [Read more »](#)

# Additional Resources

## Information from European Institutions, International Organisations and Centres for Disease Control and Prevention

**European Union.** Re-open EU: interactive tool with country information for travel and transportation [Read more »](#)

**European Commission.** Coronavirus response. [Read more »](#)

**European Parliament.** The EU's response to the coronavirus. [Read more »](#)

**EU Healthy Gateways:** [Published guidance and reports for COVID-19](#)

**European Agency for Safety and Health (OSHA).** COVID-19: Resources for the workplace: EU guidance, telework, resources from EU and international organisations. [Read more »](#)

**European Food Safety Authority (EFSA).** COVID-19. [Read more »](#)

**European Medicines Agency (EMA):** Treatments and vaccines for COVID-19. [Latest updates on COVID-19.](#)

**European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).** COVID-19 and drugs. [Read more »](#)

**Health Systems Response Monitor:** [COVID-19 Health System Response Monitor](#) designed in response to the COVID-19 outbreak to collect and organize up-to-date information on how countries are responding to the crisis

**World Health Organization (WHO).** Coronavirus disease (COVID-19) pandemic. [Read more »](#)

**Food and Agriculture Organization of the UN (FAO):** Novel Coronavirus. [Read more »](#)

**African Centres of Disease Control and Prevention.** [Read more »](#)

**Public Health Agency of Canada.** [Read more »](#)

**Chinese Center for Disease Control and Prevention.** [Read more »](#)

**Israel Center for Disease Control, Ministry of Health.** [Read more »](#)

**Korea Disease Control and Prevention Agency.** [Read more »](#)

**Ministry of Health of Mexico.** [Read more »](#)

**UK Health Security Agency.** [Read more »](#)

**US Centers for Disease Control and Prevention.** [Read more »](#)

## COVID-19 information pages of EU/EEA Member States



[Austria »](#)



[Belgium »](#)



[Bulgaria »](#)



[Croatia »](#)



[Cyprus »](#)



[Czechia »](#)



[Denmark »](#)



[Estonia »](#)



[Finland »](#)



[France »](#)



[Germany »](#)



[Greece »](#)



[Hungary »](#)



[Iceland »](#)



[Ireland »](#)



[Italy »](#)



[Latvia »](#)



[Liechtenstein »](#)



[Lithuania »](#)



[Luxembourg »](#)



[Malta »](#)



[Netherlands »](#)



[Norway »](#)



[Poland »](#)



[Portugal »](#)



[Romania »](#)



[Slovakia »](#)



[Slovenia »](#)



[Spain »](#)



[Sweden »](#)

## Living Evidence Summaries

**COAP:** [COVID-19 Open Access Project](#) from the Institute of Social and Preventive Medicine ([ISPM](#)). This database is updated daily with published articles from Pubmed and EMBASE and with preprints from medRxiv and bioRxiv.

**COVID-END McMaster Health Forum:** [living evidence syntheses](#) on a variety of topics including efficacy and effectiveness of COVID-19 vaccines in the presence of variants of concern (VOCs).

**EPPI Centre:** [COVID-19](#): a living systematic map of the evidence. Up-to-date map of the current evidence that are partitioned into broad domains for easy exploration.

**MAGIC project (MAGIC Evidence Ecosystem Foundation, theBMJ, WHO):** [Drug treatments for COVID-19](#) living systematic review and network meta-analysis and a [living WHO guideline on drugs for COVID-19](#)

**NMA initiative:** [COVID-19 – living initiative](#). Living mapping and living systematic review of Covid-19 trials.

**PregCOV-19LSR** by the University of Birmingham. Series of living systematic reviews (LSR) involving pregnant and postnatal women at risk, suspected, and diagnosed to have COVID-19 according to recommended methods. [Read more »](#)

**WHO:** [Living WHO guideline on drugs for COVID-19](#) (published by theBMJ)

## Science Updates

**Centre for Evidence-Based Medicine CEBM:** [Oxford COVID-19 Evidence Service](#). Rapid reviews of primary care questions relating to COVID-19.

**Cochrane:** [Cochrane Reviews](#) and related content from the Cochrane Library relating to the COVID-19 pandemic.

**COVID Reference International:** Every day the “Top 10 scientific COVID-19 papers of the day” are presented. Also provides multiple other useful links to literature. [Read more »](#)

**Evidence Aid:** [Evidence Collection](#) on Coronavirus (COVID-19). This evidence collection contains plain-language summaries of high-quality research which are available in English, and translated into French, Spanish, Portuguese, Arabic and Chinese (simplified and traditional).

**Health Information and Quality Authority Ireland:** [COVID-19 Publications](#): Clinical evidence summaries and rapid reviews on various topics.

**LitCovid:** [curated literature hub](#) for tracking up-to-date scientific information about COVID-19. It is the most comprehensive resource on the subject, providing a central access a large number of relevant articles in PubMed.

**US Centers for Disease Control and Prevention:** [COVID-19 Science Updates](#) providing brief summaries of new COVID-19-related studies on many topics, including epidemiology, clinical treatment and management, laboratory science, and modeling. The summaries are released every Tuesday and Friday.

**VA-ESP COVID-19 Reviews:** [U.S. Veterans' Affairs \(VA\) Evidence Synthesis Program](#) - Inventory of living systematic reviews and 'rapid reviews', with a flag for living reviews and for reviews meeting minimum quality standards

**Wolters Kluwer:** [Clinical effectiveness COVID-19 Resources Available to All](#). View a categorized collection of all UpToDate COVID-19 content including clinical topics, algorithms, patient education and society guideline links.

**World Health Organization:** [COVID-19 Global literature on coronavirus disease](#). Literature database.